The therapeutic use of messenger RNA (mRNA) has fueled great hope to combat a wide
range of incurable diseases. Recent rapid advances in biotechnology and molecular …

The response of immune cells in cardiac injury is divided into three continuous phases:
inflammation, proliferation and maturation. The kinetics of the inflammatory and proliferation …

In a cell-free approach to regenerative therapeutics, transient application of paracrine factors
in vivo could be used to alter the behavior and fate of progenitor cells to achieve sustained …

mRNA can direct dose-dependent protein expression in cardiac muscle without genome
integration, but to date has not been shown to improve cardiac function in a safe, clinically …

To harness the potential of human pluripotent stem cells (hPSCs), an abundant supply of
their progenies is required. Here, hPSC expansion as matrix-independent aggregates in …

Myocardial infarction (MI) and heart failure (HF) are the leading causes of death in the
United States and in most other industrialized nations. MI leads to a massive loss of …

Bone has a remarkable potential for self-healing and repair, yet several injury types are non-
healing even after surgical or non-surgical treatment. Regenerative therapies that induce …

During development, cardiogenesis is orchestrated by a family of heart progenitors that build
distinct regions of the heart. Each region contains diverse cell types that assemble to form …

Most of the mammalian heart is formed from mesodermal progenitors in the first and second
heart fields (FHF and SHF), whereby the FHF gives rise to the left ventricle and parts of the …

Vascular endothelial growth factor A (VEGF-A) has therapeutic cardiovascular effects, but
delivery challenges have impeded clinical development. We report the first clinical study of …